Gastric Cancer Roundtables
The panel discusses considerations around treating peritoneal gastric cancer, including the role of HIPEC. In part three of their discussion, the panel explores the role of ADCs in treating gastric and esophageal cancers. The panelists discuss the impact of biomarkers on personalized gastric cancer care, including ctDNA, claudin 18.2, and PD-L1. An expert panel of GI oncologists debates recent advancements in biomarker-driven strategies for GI cancer care.